Zanubrutinib Shows Worth Against Standard CLL Drugs Zanubrutinib Shows Worth Against Standard CLL Drugs
Patients with chronic lymphocytic leukemia could soon be offered a novel treatment option after trial data showed zanubrutinib improves outcomes against standard therapies.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Health | Hematology | Leukemia